Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.

Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA.

Oncologist. 2019 Oct 14. pii: theoncologist.2019-0446. doi: 10.1634/theoncologist.2019-0446. [Epub ahead of print]

PMID:
31611330
2.

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.

Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, Patel KR, Barry PN, Rao RD.

Adv Radiat Oncol. 2019 Apr 3;4(3):453-457. doi: 10.1016/j.adro.2019.03.011. eCollection 2019 Jul-Sep.

3.

Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.

Buckingham L, Mitchell R, Maienschein-Cline M, Green S, Hu VH, Cobleigh M, Rotmensch J, Burgess K, Usha L.

Hered Cancer Clin Pract. 2019 Jul 16;17:21. doi: 10.1186/s13053-019-0117-5. eCollection 2019.

4.

Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.

Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, Cobleigh MA.

Breast Cancer Res Treat. 2019 Sep;177(2):325-333. doi: 10.1007/s10549-019-05320-x. Epub 2019 Jun 17.

PMID:
31209687
5.

Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer.

Shammo JM, Usha L, Richardson KJ, Elliott E, Dewdney S, Venugopal P, Cobleigh M, Kuzel TM.

J Oncol Pract. 2019 Jul;15(7):405-407. doi: 10.1200/JOP.18.00705. Epub 2019 Jun 14. No abstract available.

PMID:
31199709
6.

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M.

Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. Epub 2018 Dec 28.

PMID:
30593513
7.

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L.

PLoS One. 2018 Apr 16;13(4):e0195497. doi: 10.1371/journal.pone.0195497. eCollection 2018.

8.

Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.

Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L.

Breast Cancer Res Treat. 2017 Nov;166(1):315-319. doi: 10.1007/s10549-017-4393-3. Epub 2017 Jul 12.

PMID:
28702897
9.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

10.

Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?

Brann AM, Cobleigh MA, Okwuosa TM.

JAMA Oncol. 2016 Sep 1;2(9):1123-4. doi: 10.1001/jamaoncol.2016.1288. No abstract available.

PMID:
27280310
11.

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M.

Ann Oncol. 2016 Jun;27(6):1029-34. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8.

PMID:
26961151
12.

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM.

Breast Cancer Res Treat. 2016 Feb;156(1):33-43. doi: 10.1007/s10549-016-3729-8. Epub 2016 Feb 25.

13.

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.

Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW.

Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12.

14.

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.

Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY.

Cancer Chemother Pharmacol. 2014 Aug;74(2):399-410. doi: 10.1007/s00280-014-2500-2. Epub 2014 Jun 18.

15.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N.

Breast Cancer Res Treat. 2013 Nov;142(2):415-21. doi: 10.1007/s10549-013-2755-z. Epub 2013 Nov 8.

16.

HER2-directed treatment of metastatic breast cancer: unanswered questions.

Rao R, Cobleigh M.

Oncology (Williston Park). 2013 Mar;27(3):176, 178, 180. No abstract available.

17.

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS.

Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22.

18.

A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Cobleigh MA, Wei X, Robek MD.

J Virol. 2013 Mar;87(5):2969-73. doi: 10.1128/JVI.02111-12. Epub 2012 Dec 26.

19.

Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis.

Cobleigh MA, Robek MD.

Am J Pathol. 2013 Jan;182(1):21-8. doi: 10.1016/j.ajpath.2012.08.043. Epub 2012 Nov 14. Review.

20.

Adjuvant endocrine therapy for breast cancer.

Rao RD, Cobleigh MA.

Oncology (Williston Park). 2012 Jun;26(6):541-7, 550, 552 passim. Review.

21.

Introduction.

DeMare LE, Cobleigh MA.

Yale J Biol Med. 2012 Mar;85(1):1-2. No abstract available.

22.

The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Cobleigh MA, Bradfield C, Liu Y, Mehta A, Robek MD.

J Virol. 2012 Apr;86(8):4253-61. doi: 10.1128/JVI.05991-11. Epub 2012 Feb 15.

23.

Pathologic findings in MRI-guided needle core biopsies of the breast in patients with newly diagnosed breast cancer.

Siziopikou KP, Jokich P, Cobleigh M.

Int J Breast Cancer. 2011;2011:613285. doi: 10.4061/2011/613285. Epub 2010 Dec 1.

24.

A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus.

Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD.

Gastroenterology. 2011 Nov;141(5):1897-906. doi: 10.1053/j.gastro.2011.06.051. Epub 2011 Jun 25.

25.

Other options in the treatment of advanced breast cancer.

Cobleigh MA.

Semin Oncol. 2011 Jun;38 Suppl 2:S11-6. doi: 10.1053/j.seminoncol.2011.04.005. Review.

PMID:
21600380
26.

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.

Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H.

Clin Cancer Res. 2011 Jan 15;17(2):372-81. doi: 10.1158/1078-0432.CCR-10-1791. Epub 2011 Jan 11.

27.

Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC.

Med Oncol. 2011 Dec;28 Suppl 1:S39-47. doi: 10.1007/s12032-010-9682-1. Epub 2010 Sep 28.

28.

A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD.

J Virol. 2010 Aug;84(15):7513-22. doi: 10.1128/JVI.00200-10. Epub 2010 May 26.

29.

ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast.

Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):997-1002. doi: 10.1016/j.ijrobp.2008.10.080. Review.

PMID:
19251087
30.

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100.

J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070.

31.

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP.

Breast Cancer Res Treat. 2009 May;115(1):115-21. doi: 10.1007/s10549-008-0055-9. Epub 2008 May 22.

PMID:
18496750
32.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

J Clin Oncol. 2008 Apr 10;26(11):1810-6. doi: 10.1200/JCO.2007.14.5375. Epub 2008 Mar 17.

PMID:
18347007
33.

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE.

N Engl J Med. 2007 Dec 27;357(26):2666-76.

34.

Targeting metastatic and advanced breast cancer.

Moore S, Cobleigh MA.

Semin Oncol Nurs. 2007 Feb;23(1):37-45. Review.

PMID:
17303515
36.
37.
38.

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D.

J Clin Oncol. 2006 Jun 20;24(18):2786-92.

PMID:
16782917
39.

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31.

40.

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI.

JAMA. 2005 Oct 19;294(15):1925-33.

PMID:
16234499
41.

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ.

Clin Breast Cancer. 2005 Aug;6(3):240-6.

PMID:
16137435
42.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS.

J Clin Oncol. 2005 Feb 1;23(4):792-9.

PMID:
15681523
43.

Determination of factors associated with hospitalization in breast cancer survivors.

Oleske DM, Cobleigh MA, Phillips M, Nachman KL.

Oncol Nurs Forum. 2004 Nov 16;31(6):1081-8.

PMID:
15547631
44.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
45.

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW.

Clin Cancer Res. 2004 Mar 15;10(6):1971-5.

46.

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ.

J Clin Oncol. 2004 Mar 15;22(6):1063-70.

PMID:
15020607
47.

A case of herceptin cardiotoxicity.

Cobleigh M, Somberg JC.

Am J Ther. 2004 Jan-Feb;11(1):74-6. No abstract available.

PMID:
14704598
48.

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A.

Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24.

PMID:
14613032
49.

Is trastuzumab every three weeks ready for prime time?

Cobleigh M, Frame D.

J Clin Oncol. 2003 Nov 1;21(21):3900-1. Epub 2003 Sep 24. No abstract available.

PMID:
14507945
50.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2003 Jul 1;21(13):2597-9. Epub 2003 May 5. No abstract available.

PMID:
12732612

Supplemental Content

Loading ...
Support Center